Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7808275 | 0.97 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1MAOAMAOBOPRK1 | |
| SCHEMBL3250253 | 0.77 | OPRK1 (0.51) | SIGMAR1ALDH1A1OPRK1 | |
| SCHEMBL3247032 | 0.77 | OPRK1 (0.51) | SIGMAR1ALDH1A1OPRK1 | |
| SCHEMBL3252831 | 0.77 | OPRK1 (0.54) | SIGMAR1ALDH1A1OPRK1CHRM2CHRM4 | |
| SCHEMBL3252835 | 0.77 | OPRK1 (0.54) | SIGMAR1ALDH1A1OPRK1CHRM2CHRM4 | |
| SCHEMBL12881261 | 0.73 | DPP4 (0.41) | SIGMAR1ALDH1A1OPRK1DRD2DRD4 | |
| SCHEMBL7456872 | 0.71 | LMNA (0.42) | SIGMAR1ALDH1A1OPRK1ACHE | |
| SCHEMBL771596 | 0.70 | CYP3A4 (0.41) | SIGMAR1ALDH1A1OPRK1DRD2DRD4 | |
| SCHEMBL632289 | 0.70 | SLC6A9 (0.38) | OPRK1DRD2DRD4DRD3 | |
| SCHEMBL11122549 | 0.69 | CHRM2 (0.41) | OPRK1CHRM2CHRM4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779143-B2 | Crystalline forms of maraviroc phosphate and process for maraviroc amorphous form | HETERO RESEARCH FOUNDATION (IN) | 2014-07-15 | — | — | US | disclosed |
| US-20130211091-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | HETERO RESEARCH FOUNDATION (IN) | 2013-08-15 | — | — | US | disclosed |
| EP-2611446-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | Hetero Research Foundation (IN) | 2013-07-10 | — | — | EP | disclosed |
| EP-1990341-B1 | Triazolyl tropane derivatives as CCR5 modulators | PFIZER (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2012029067-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | HETERO RESEARCH FOUNDATION (IN) | 2012-03-08 | — | — | WO | disclosed |
| EP-1990341-A1 | Triazolyl tropane derivatives as CCR5 modulators | Pfizer Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1526134-B1 | TRIAZOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LTD (GB) | 2008-09-03 | — | — | EP | disclosed |
| US-7368460-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040067977-A1 | Tropane derivatives useful in therapy | PFIZER, INC. | 2004-04-08 | — | — | US | disclosed |
| EP-1284974-B1 | TRIAZOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LTD (GB) | 2004-03-03 | — | — | EP | disclosed |
| US-6667314-B2 | For therapy of respiratory disorder including adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis or chronic sinusitis | PFIZER, INC. | 2003-12-23 | — | — | US | disclosed |
| US-6586430-B1 | Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| US-20020013337-A1 | Tropane derivatives useful in therapy | PHIVCO-1 LLC | 2002-01-31 | — | — | US | disclosed |
| US-4459300-A | ANTIEMETICS, GASTROINTESTINAL DISORDERS, CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | BEECHAM GROUP P.L.C. (GB) | 1984-07-10 | — | — | US | disclosed |
| EP-0102195-A2 | Substituted aza bicycloalkyl derivatives with dopamine antagonist activity | BEECHAM GROUP PLC (GB) | 1984-03-07 | — | — | EP | disclosed |
| EP-0069482-A1 | Azabicycloalkyl benzamides, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013337-A1 | Tropane derivatives useful in therapy | ADRB3, ADRA1A, ADRB2 | SIGMAR1 83/4885ALDH1A1 454/4885MAOA 29/4885 |
| US-20040067977-A1 | Tropane derivatives useful in therapy | ADRB3, ADRA1A, ADRB2 | SIGMAR1 83/4885ALDH1A1 454/4885MAOA 29/4885 |
| US-20130211091-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | PNP, TYMP, SAMHD1 | SIGMAR1 2297/4885ALDH1A1 4072/4885MAOA 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.